The treatment of hemophilia is very expensive, costing the average individual with hemophilia upwards of $140,000 per year, and usually consists of injecting a concentrated form of the missing clotting factor into the bloodstream.

A single infusion of factor, when administered early, is often effective in controlling most minor bleeding episodes. More serious bleeds may require several infusions over several days. Individuals with mild hemophilia A can often be treated with a synthetic hormone called desmopressin acetate (DDAVP) which may boost factor VIII levels high enough to make treatment with clotting factor unnecessary.

Treatment is more complicated for some individuals whose immune systems produce antibodies, or inhibitors, which attack the factor molecule and render it ineffective. The development of inhibitors occurs in approximately 20 to 30% of individuals with hemophilia A and 2-3% of the individuals with hemophilia B. The development of inhibitors is a serious complication, which requires an individual treatment plan and close monitoring.